Abstract: The present disclosure provides compositions for regulating glucose metabolism. The compositions provide for reduced levels of p75NTR and/or reduced binding of p75NTR to a GTPase such as Rab31 or Rab5. The compositions are useful in methods of regulating glucose metabolism, which methods are also provided.

Abstract: The present invention provides compositions exhibiting in vivo activity of fibrin in an in vitro setting, in vitro assays comprising such compositions, methods of producing such compositions, and methods of using such compositions and assays. The compositions of the invention include molecules with the biochemical properties of 1) high affinity binding to fibrin receptors and 2) activation of cell-signaling systems comparable to that observed in vivo by fibrin. The fibrin compositions of the invention are compatible both in biochemical assays and cell-based assays, and thus useful for in vitro assays for screening of test agents that modulate cell activation and/or signaling pathways mediated by fibrin or associated with fibrin activity.

Abstract: This invention provides methods for promoting and/or restoring neurite outgrowth and neuronal regeneration by contacting an injured neuron with an inhibitor of low density lipoprotein receptor-related protein-1 (LRP-1).

Abstract: The present invention provides non-human animal models of neuronal injury and/or cognitive dysfunction and methods of making and using such animal models. The animal models of the invention are particularly suited to assessing neurodegeneration in selected regions of interest in the CNS, and thus especially useful for testing the therapeutic efficacy of agents targeting neurodegeneration associated with aging, neurodegenerative diseases, autoimmunity and trauma (e.g., ischemia).

Abstract: The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise administration of antibodies directed towards peptides that bind to receptors important in disease progression, thus attenuating the disease.

Abstract: The present invention provides an isolated antibody that binds a fibrin or fibrinogen ?C domain. In various aspects, the antibody inhibits microglial adhesion to the fibrin or fibrinogen ?C domain, inhibits Mac-1 binding to the fibrin or fibrinogen ?C domain, and/or suppresses clinical symptoms of Experimental Autoimmune Encephalomyelitis (EAE). Various methods of using the antibodies, pharmaceutical compositions, kits, vectors, cells comprising the vectors, and antibody generating methods are provided.

Abstract: The present disclosure provides compositions for regulating glucose metabolism. The compositions provide for reduced levels of p75NTR and/or reduced binding of p75NTR to a GTPase such as Rab31 or Rab5. The compositions are useful in methods of regulating glucose metabolism, which methods are also provided.

Abstract: This invention provides methods for promoting and/or restoring neurite outgrowth and neuronal regeneration by contacting an injured neuron with an inhibitor of low density lipoprotein receptor-related protein-1 (LRP-1).

Abstract: The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise administration of antibodies directed towards peptides that bind to receptors important in disease progression, thus attenuating the disease.

Abstract: The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise administration of antibodies directed towards peptides that bind to receptors important in disease progression, thus attenuating the disease.

Abstract: The present invention provides an isolated antibody that binds a fibrin or fibrinogen ?C domain. In various aspects, the antibody inhibits microglial adhesion to the fibrin or fibrinogen ?C domain, inhibits Mac-1 binding to the fibrin or fibrinogen ?C domain, and/or suppresses clinical symptoms of Experimental Autoimmune Encephalomyelitis (EAE). Various methods of using the antibodies, pharmaceutical compositions, kits, vectors, cells comprising the vectors, and antibody generating methods are provided.

Abstract: The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise administration of antibodies directed towards peptides that bind to receptors important in disease progression, thus attenuating the disease.

Abstract: The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise peptides that bind to receptors important in disease progression, thus attenuating the disease.

Abstract: The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise peptides that bind to receptors important in disease progression, thus attenuating the disease.

Abstract: The inventors have succeeded in discovering that the p75 neurotrophin receptor (p75NTR) is directly involved in the degradation of cAMP via interaction of its intracellular domain with phosphodiesterase 4A4/5 (PDE4A4/5). Provided herein are methods and compositions for the treatment of conditions of PDE4A4/5 and p75NTR expression (such as pulmonary disease and nerve regeneration) by blocking the interaction of PDE4A4/5 and p75NTR, as well as methods for the screening of agents useful in such applications.

Abstract: The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise peptides that bind to receptors important in disease progression, thus attenuating the disease.